Zhejiang AngLiKang Pharmaceutical (SHE:002940) said its subsidiary, Hunan Kerui Biopharmaceutical, received approval from China's National Medical Products Administration for its Finasteride active pharmaceutical ingredient, according to a Thursday filing with the Shenzhen bourse.
Finasteride is used for benign prostatic hyperplasia (BPH) and male pattern baldness. The approval, valid until Feb. 11, 2030, allows the company to proceed with production and sales pending GMP compliance confirmation. This approval expands Anglikang's API portfolio.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.